GlobeNewswire 2021-03-04 GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
GlobeNewswire 2021-03-03 Transparency notification received from The Capital Group
GlobeNewswire 2021-02-18 Pipeline and capital for growth
GlobeNewswire 2021-02-10 Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
GlobeNewswire 2021-02-09 The Capital Group holds 10.03% of Galapagos shares
GlobeNewswire 2021-01-21 NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis
GlobeNewswire 2021-01-20 Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
GlobeNewswire 2021-01-11 Gilead holds 25.54% of Galapagos shares
GlobeNewswire 2021-01-07 OXURION to Participate in Upcoming Investor Meetings
GlobeNewswire 2021-01-06 Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2021-01-04 Selvita completes acquisition of Fidelta from Galapagos
GlobeNewswire 2020-12-23 Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
GlobeNewswire 2020-12-15 Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca...
GlobeNewswire 2020-12-13 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - G...
GlobeNewswire 2020-12-04 Galapagos increases share capital through subscription right exercises
GlobeNewswire 2020-12-01 Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney diseas...
GlobeNewswire 2020-11-30 Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept t...
GlobeNewswire 2020-11-23 Selvita to acquire Fidelta from Galapagos
GlobeNewswire 2020-11-09 First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
GlobeNewswire 2020-11-09 OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
GlobeNewswire 2020-11-05 OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis
GlobeNewswire 2020-11-05 Galapagos reports Q3 2020 results
GlobeNewswire 2020-11-02 EUROPEAN  MEDICINES  AGENCY  VALIDATES  MARKETING  APPLICATION  FOR  FILGOTINIB  FOR  THE  TREATMENT...
GlobeNewswire 2020-10-27 Galapagos’ R&D Roundtable showcases Toledo program
GlobeNewswire 2020-10-15 Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S2010...